DBV shares are crushed — while rival Aimmune soars — after PhIII flop for peanut allergy med
A couple of years ago, Paris-based DBV Technologies $DBVT set aside $95 million from an offering for its Phase III trial of a new therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
